17.3 Laboratory Mathematics

Rh Immune Globulin Dose Calculation

Calculating Rh immune globulin (RhIG) dose is one of the highest-yield calculation types on the SBB exam because it combines a laboratory result — the fetal-maternal hemorrhage screen — with a fixed regulatory rounding rule. The workflow:

1. Estimate maternal blood volume — commonly assumed as 5000 mL for an average-sized woman, or calculated as 70 mL/kg x body weight when a weight-based estimate is required.
2. Determine the percentage of fetal cells in the maternal circulation from a Kleihauer-Betke (KB) acid elution stain or flow cytometry (fetal cells resist acid elution and appear pink or red against ghost adult cells).
3. Calculate the fetal-maternal hemorrhage (FMH) volume of whole fetal blood: FMH (mL) = maternal blood volume x (% fetal cells / 100).
4. Divide the FMH volume by 30 mL — the amount of whole fetal blood (equivalent to 15 mL of fetal RBCs) that one standard 300 microgram RhIG dose protects against.
5. Apply the standard AABB rounding rule: if the result is a whole number, add one additional vial; if it is not a whole number, round down to the nearest whole number and then add one vial. This built-in margin protects against underdosing from estimation error.

Worked example: a maternal blood volume of 5000 mL and a KB stain showing 0.6% fetal cells gives FMH = 5000 x 0.006 = 30 mL of fetal whole blood. Dividing by 30 gives exactly 1.0, a whole number, so per the rounding rule, one additional vial is added: the patient needs 2 vials of RhIG, not 1. A second worked example: FMH = 5000 x 0.008 = 40 mL; 40 / 30 = 1.33, which rounds down to 1, then one vial is added, for a total of 2 vials. A frequent SBB trap is forgetting the "add one" step and reporting the raw quotient as the final dose.

Serial Dilutions And Antibody Titers

Blood bank titration studies — maternal alloantibody titers in HDFN monitoring, or resolving weak or high-titer antibodies — use doubling (twofold) serial dilutions rather than the 1:10 dilutions common in chemistry. Each tube after the first represents half the concentration of the one before it: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, and so on. The titer is reported as the reciprocal of the highest dilution showing macroscopic (1+ or greater) agglutination — if the last tube with visible reactivity is the 1:64 tube, the titer is reported as 64.

A critical titer (commonly 16 or 32, depending on institutional policy and reference laboratory practice) in maternal antibody workups for antibodies known to cause HDFN, such as anti-D or anti-Kell, triggers referral for fetal surveillance (for example, middle cerebral artery Doppler). Values are compared against a baseline drawn earlier in pregnancy, and a rise of two or more tubes (for example, 8 to 32) is considered a significant increase even if the absolute value has not yet crossed the critical threshold. A common exam trap is treating titer changes additively instead of doubling: going from 1:8 to 1:16 is only a one-tube (twofold) increase, not a major jump, while 1:8 to 1:32 is a two-tube, fourfold increase that is clinically significant regardless of where the critical titer line sits.

Corrected Count Increment For Platelet Transfusion

The corrected count increment (CCI) quantifies whether a platelet transfusion achieved the expected rise in a patient's platelet count, adjusting for the patient's body size and the number of platelets actually transfused:

CCI = [(post-transfusion platelet count minus pre-transfusion platelet count) (/µL) x body surface area (m²)] / number of platelets transfused (x10¹¹)

A post-transfusion sample is typically drawn at 1 hour (to assess immediate recovery) and again at 18–24 hours (to assess survival). Generally accepted thresholds are a 1-hour CCI at or above 7,500–10,000 and an 18–24 hour CCI at or above 4,500–5,000 for an adequate response. Values persistently below these thresholds on two or more sequential transfusions of ABO-compatible, fresh platelets define platelet refractoriness, which shifts the workup toward immune causes (HLA or platelet-specific antibodies, requiring HLA-matched or crossmatch-compatible platelets) versus nonimmune causes (fever, sepsis, disseminated intravascular coagulation, splenomegaly, amphotericin B).

Worked example: a patient with a body surface area of 1.8 m² has a pre-transfusion platelet count of 10,000/µL and a 1-hour post-transfusion count of 40,000/µL after receiving one apheresis platelet unit containing 3.5 x10¹¹ platelets. CCI = [(40,000 − 10,000) x 1.8] / 3.5 = (30,000 x 1.8) / 3.5 = 54,000 / 3.5 = 15,429. This comfortably exceeds the 1-hour adequacy threshold, indicating a good immediate response and arguing against refractoriness at this time point.

Unit Conversions And Blood Volume Estimates

The SBB exam expects fluency converting between the units that show up in donor and dosing calculations:

Worked example combining volume and dose logic: a 60 kg patient has an estimated blood volume of 60 x 70 = 4200 mL. If a KB stain shows 0.4% fetal cells, FMH = 4200 x 0.004 = 16.8 mL; 16.8 / 30 = 0.56, which rounds down to 0, then one vial is added, for a total of 1 vial of RhIG — illustrating that a smaller, weight-based blood volume estimate (rather than the default 5000 mL assumption) can change the vial count. As with every laboratory mathematics item on this exam, solve the number, then re-read the question stem to confirm which quantity was actually asked for; a correctly calculated FMH volume reported instead of the final vial count is a wrong answer even though the arithmetic was right.